Teresa von Linde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Teresa von Linde has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Alberto G. Conti
Department of Pathology, University of Cambridge, Cambridge, UK
32 shared publications - Alexander C. Evans
Department of Pathology, University of Cambridge, Cambridge, UK
32 shared publications - Charlotte J. Imianowski
Department of Pathology, University of Cambridge, Cambridge, UK
32 shared publications - Jie Yang
Department of Pathology, University of Cambridge, Cambridge, UK
32 shared publications - Rahul Roychoudhuri
Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK
32 shared publications - Alexander J. Wesolowski
Department of Pathology, University of Cambridge, Cambridge, UK
31 shared publications
Latest Publications
- 3 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6815) , 1036-1044
Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species
Reactive oxygen species (ROS) promote genomic instability and fuel oncogenic signaling in cancer, but antioxidant therapies have so far failed to improve, or worsen, cancer outcomes. Emerging data suggest that T cells depend on ROS for signal transduction. In this study, we show that tumors exploit this dependency, releasing antioxidant enzymes into the tumor environment to suppress T cell–mediated antitumor immunity. The interstitial fluid of tumors possesses potent antioxidant activity, associated with enrichment of the antioxidant enzyme peroxiredoxin 1 (PRDX1). Extracellular PRDX1 deprives T cells of ROS, preventing oxidative inactivation of phosphatases required for T cell receptor–driven kinase signaling and effector function. Prdx1 is up-regulated upon cancer immunoediting, and loss of PRDX1 within tumors enhances antitumor immunity and immunotherapy responses. These findings define a redox-dependent mechanism of tumor immunosuppression that is potentially amenable to therapeutic intervention.
- 3 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6815) , 1036-1044
Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species
Reactive oxygen species (ROS) promote genomic instability and fuel oncogenic signaling in cancer, but antioxidant therapies have so far failed to improve, or worsen, cancer outcomes. Emerging data suggest that T cells depend on ROS for signal transduction. In this study, we show that tumors exploit this dependency, releasing antioxidant enzymes into the tumor environment to suppress T cell–mediated antitumor immunity. The interstitial fluid of tumors possesses potent antioxidant activity, associated with enrichment of the antioxidant enzyme peroxiredoxin 1 (PRDX1). Extracellular PRDX1 deprives T cells of ROS, preventing oxidative inactivation of phosphatases required for T cell receptor–driven kinase signaling and effector function. Prdx1 is up-regulated upon cancer immunoediting, and loss of PRDX1 within tumors enhances antitumor immunity and immunotherapy responses. These findings define a redox-dependent mechanism of tumor immunosuppression that is potentially amenable to therapeutic intervention.
- Open Access
- 16 January 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 436-451
Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy
Adoptive T cell therapies are limited by poor persistence of transferred cells. Attempts to enhance persistence have focused on genetic induction of constitutively hyperactivated but potentially oncogenic T cell states. Physiological T cell responses are maintained by quiescent stem-like/memory cells dependent upon the transcription factor BACH2. Here we show that quantitative control of BACH2 dosage regulates differentiation along the continuum of stem and effector CD8⁺ T cell states, enabling engineering of synthetic states with persistent antitumor activity. While conventional high-level overexpression of BACH2 enforces quiescence and hinders tumor control, low-dose BACH2 expression promotes persistence without compromising effector function, enhancing anticancer efficacy. Mechanistically, low-dose BACH2 partially attenuates Jun occupancy at highly AP-1-dependent genes, restraining terminal differentiation while preserving effector programs. Similarly, dose optimization enables effective deployment of quiescence factor FOXO1. Thus, quantitative control of gene payloads yields qualitative effects on outcome with implications for quiescence factor deployment in cell therapy.
- 16 January 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 436-451
Open AccessFine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy
Adoptive T cell therapies are limited by poor persistence of transferred cells. Attempts to enhance persistence have focused on genetic induction of constitutively hyperactivated but potentially oncogenic T cell states. Physiological T cell responses are maintained by quiescent stem-like/memory cells dependent upon the transcription factor BACH2. Here we show that quantitative control of BACH2 dosage regulates differentiation along the continuum of stem and effector CD8⁺ T cell states, enabling engineering of synthetic states with persistent antitumor activity. While conventional high-level overexpression of BACH2 enforces quiescence and hinders tumor control, low-dose BACH2 expression promotes persistence without compromising effector function, enhancing anticancer efficacy. Mechanistically, low-dose BACH2 partially attenuates Jun occupancy at highly AP-1-dependent genes, restraining terminal differentiation while preserving effector programs. Similarly, dose optimization enables effective deployment of quiescence factor FOXO1. Thus, quantitative control of gene payloads yields qualitative effects on outcome with implications for quiescence factor deployment in cell therapy.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 1: OX40 and CD137 are highly expressed on Treg cells. Representative plots showing OX40+ (left) and CD137+ (right) SP resting or activated cells from the spleen and tumor on day 18 post tumor implantation. ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. One-way ANOVA with Tukey’s correction for multiple comparisons. Bars and error are mean and s.e.m.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 1: OX40 and CD137 are highly expressed on Treg cells. Representative plots showing OX40+ (left) and CD137+ (right) SP resting or activated cells from the spleen and tumor on day 18 post tumor implantation. ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. One-way ANOVA with Tukey’s correction for multiple comparisons. Bars and error are mean and s.e.m.
- 28 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 387 (6741) , eadq8331
Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins
Breakdown of every transmembrane protein trafficked to lysosomes requires proteolysis of their hydrophobic helical transmembrane domains. Combining lysosomal proteomics with functional genomic datasets, we identified lysosomal leucine aminopeptidase (LyLAP; formerly phospholipase B domain–containing 1) as the hydrolase most tightly associated with elevated endocytosis. Untargeted metabolomics and biochemical reconstitution demonstrated that LyLAP is a processive monoaminopeptidase with preference for amino-terminal leucine. This activity was necessary and sufficient for the breakdown of hydrophobic transmembrane domains. LyLAP was up-regulated in pancreatic ductal adenocarcinoma (PDA), which relies on macropinocytosis for nutrient uptake. In PDA cells, LyLAP ablation led to the buildup of undigested hydrophobic peptides, lysosomal membrane damage, and growth inhibition. Thus, LyLAP enables lysosomal degradation of membrane proteins and protects lysosomal integrity in highly endocytic cancer cells.
- 28 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 387 (6741) , eadq8331
Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins
Breakdown of every transmembrane protein trafficked to lysosomes requires proteolysis of their hydrophobic helical transmembrane domains. Combining lysosomal proteomics with functional genomic datasets, we identified lysosomal leucine aminopeptidase (LyLAP; formerly phospholipase B domain–containing 1) as the hydrolase most tightly associated with elevated endocytosis. Untargeted metabolomics and biochemical reconstitution demonstrated that LyLAP is a processive monoaminopeptidase with preference for amino-terminal leucine. This activity was necessary and sufficient for the breakdown of hydrophobic transmembrane domains. LyLAP was up-regulated in pancreatic ductal adenocarcinoma (PDA), which relies on macropinocytosis for nutrient uptake. In PDA cells, LyLAP ablation led to the buildup of undigested hydrophobic peptides, lysosomal membrane damage, and growth inhibition. Thus, LyLAP enables lysosomal degradation of membrane proteins and protects lysosomal integrity in highly endocytic cancer cells.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Data from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Regulatory T cells (Treg) are highly enriched within many tumors and suppress immune responses to cancer. There is intense interest in reprogramming Tregs to contribute to antitumor immunity. OX40 and CD137 are expressed highly on Tregs, activated and memory T cells, and NK cells. In this study, using a novel bispecific antibody targeting mouse OX40 and CD137 (FS120m), we show that OX40/CD137 bispecific agonism induces potent antitumor immunity partially dependent upon IFNγ production by functionally reprogrammed Tregs. Treatment of tumor-bearing animals with OX40/CD137 bispecific agonists reprograms Tregs into both fragile Foxp3+ IFNγ+ Tregs with decreased suppressive function and lineage-instable Foxp3− IFNγ+ ex-Tregs. Treg fragility is partially driven by IFNγ signaling, whereas Treg instability is associated with reduced IL2 responsiveness upon treatment with OX40/CD137 bispecific agonists. Importantly, conditional deletion of Ifng in Foxp3+ Tregs and their progeny partially reverses the antitumor efficacy of OX40/CD137 bispecific agonist therapy, revealing that reprogramming of Tregs into IFNγ-producing cells contributes to the anti-tumor efficacy of OX40/CD137 bispecific agonists. These findings provide insights into mechanisms by which bispecific agonist therapies targeting costimulatory receptors highly expressed by Tregs potentiate antitumor immunity in mouse models.Significance:The bispecific antibody FS120, an immunotherapy currently being tested in the clinic, partially functions by inducing anti-tumor activity of Tregs, which results in tumor rejection.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Regulatory T cells (Treg) are highly enriched within many tumors and suppress immune responses to cancer. There is intense interest in reprogramming Tregs to contribute to antitumor immunity. OX40 and CD137 are expressed highly on Tregs, activated and memory T cells, and NK cells. In this study, using a novel bispecific antibody targeting mouse OX40 and CD137 (FS120m), we show that OX40/CD137 bispecific agonism induces potent antitumor immunity partially dependent upon IFNγ production by functionally reprogrammed Tregs. Treatment of tumor-bearing animals with OX40/CD137 bispecific agonists reprograms Tregs into both fragile Foxp3+ IFNγ+ Tregs with decreased suppressive function and lineage-instable Foxp3− IFNγ+ ex-Tregs. Treg fragility is partially driven by IFNγ signaling, whereas Treg instability is associated with reduced IL2 responsiveness upon treatment with OX40/CD137 bispecific agonists. Importantly, conditional deletion of Ifng in Foxp3+ Tregs and their progeny partially reverses the antitumor efficacy of OX40/CD137 bispecific agonist therapy, revealing that reprogramming of Tregs into IFNγ-producing cells contributes to the anti-tumor efficacy of OX40/CD137 bispecific agonists. These findings provide insights into mechanisms by which bispecific agonist therapies targeting costimulatory receptors highly expressed by Tregs potentiate antitumor immunity in mouse models.Significance:The bispecific antibody FS120, an immunotherapy currently being tested in the clinic, partially functions by inducing anti-tumor activity of Tregs, which results in tumor rejection.
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.